Does the media favor ZNTL or MNOV?

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 3 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 1.45 beat MediciNova's score of -0.15 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MNOV or ACB?

MediciNova presently has a consensus price target of $8.33, suggesting a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, equities analysts plainly believe MediciNova is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to MNOV or ACB?

In the previous week, Aurora Cannabis had 12 more articles in the media than MediciNova. MarketBeat recorded 15 mentions for Aurora Cannabis and 3 mentions for MediciNova. Aurora Cannabis' average media sentiment score of 0.20 beat MediciNova's score of -0.15 indicating that Aurora Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aurora Cannabis 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to MNOV or SLGL?

In the previous week, Sol-Gel Technologies had 1 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 3 mentions for MediciNova. Sol-Gel Technologies' average media sentiment score of 0.53 beat MediciNova's score of -0.15 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ANTX or MNOV?

MediciNova has higher revenue and earnings than Anthem. MediciNova is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A MediciNova $920.48K 83.95 -$12M -$0.21 N/A

Is ANTX or MNOV more profitable?

Anthem has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% MediciNova -1,168.70% -26.51% -24.39%

Does the media prefer ANTX or MNOV?

In the previous week, Anthem and Anthem both had 3 articles in the media. Anthem's average media sentiment score of 0.56 beat MediciNova's score of -0.15 indicating that Anthem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MNOV or SBTX?

MediciNova presently has a consensus price target of $8.33, indicating a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

MediciNova (MNOV) Competitors

$1.57 +0.04 (+2.61%)

As of 02:35 PM Eastern

Compare

MNOV vs. ZNTL, ACB, SLGL, ANTX, and SBTX

Should you buy MediciNova stock or one of its competitors? MediciNova's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), Sol-Gel Technologies (SLGL), Anthem (ANTX), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MediciNova compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 3 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 1.45 beat MediciNova's score of -0.15 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.9% of MediciNova shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zentalis Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

Zentalis Pharmaceuticals presently has a consensus price target of $6.75, suggesting a potential upside of 76.93%. MediciNova has a consensus price target of $8.33, suggesting a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Zentalis Pharmaceuticals has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
MediciNova	-1,168.70%	-26.51%	-24.39%

MediciNova has lower revenue, but higher earnings than Zentalis Pharmaceuticals. MediciNova is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.05	-$137.06M	-$1.95	N/A
MediciNova	$920.48K	83.95	-$12M	-$0.21	N/A

Summary

MediciNova beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does MediciNova compare to Aurora Cannabis?

MediciNova (NASDAQ:MNOV) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, Aurora Cannabis had 12 more articles in the media than MediciNova. MarketBeat recorded 15 mentions for Aurora Cannabis and 3 mentions for MediciNova. Aurora Cannabis' average media sentiment score of 0.20 beat MediciNova's score of -0.15 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurora Cannabis	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

MediciNova has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MediciNova presently has a consensus price target of $8.33, suggesting a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, equities analysts plainly believe MediciNova is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

MediciNova has higher earnings, but lower revenue than Aurora Cannabis. MediciNova is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$920.48K	83.95	-$12M	-$0.21	N/A
Aurora Cannabis	$247.82M	1.05	-$88.13M	-$1.41	N/A

Aurora Cannabis has a net margin of -32.26% compared to MediciNova's net margin of -1,168.70%. Aurora Cannabis' return on equity of 4.37% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Aurora Cannabis	-32.26%	4.37%	3.45%

Summary

MediciNova and Aurora Cannabis tied by winning 8 of the 16 factors compared between the two stocks.

How does MediciNova compare to Sol-Gel Technologies?

MediciNova (NASDAQ:MNOV) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Sol-Gel Technologies had 1 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 3 mentions for MediciNova. Sol-Gel Technologies' average media sentiment score of 0.53 beat MediciNova's score of -0.15 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MediciNova currently has a consensus target price of $8.33, indicating a potential upside of 430.79%. Sol-Gel Technologies has a consensus target price of $197.50, indicating a potential upside of 144.19%. Given MediciNova's higher possible upside, equities analysts clearly believe MediciNova is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Sol-Gel Technologies has a net margin of -910.14% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

MediciNova has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Sol-Gel Technologies has higher revenue and earnings than MediciNova. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$920.48K	83.95	-$12M	-$0.21	N/A
Sol-Gel Technologies	$19.39M	11.72	-$6.13M	-$5.64	N/A

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sol-Gel Technologies beats MediciNova on 8 of the 14 factors compared between the two stocks.

How does MediciNova compare to Anthem?

Anthem (NASDAQ:ANTX) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Anthem has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

In the previous week, Anthem and Anthem both had 3 articles in the media. Anthem's average media sentiment score of 0.56 beat MediciNova's score of -0.15 indicating that Anthem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anthem has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
MediciNova	-1,168.70%	-26.51%	-24.39%

90.5% of Anthem shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 22.6% of Anthem shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MediciNova has higher revenue and earnings than Anthem. MediciNova is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
MediciNova	$920.48K	83.95	-$12M	-$0.21	N/A

Anthem currently has a consensus price target of $9.00, indicating a potential upside of 59.15%. MediciNova has a consensus price target of $8.33, indicating a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

MediciNova beats Anthem on 10 of the 15 factors compared between the two stocks.

How does MediciNova compare to Silverback Therapeutics?

MediciNova (NASDAQ:MNOV) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, MediciNova had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for MediciNova and 0 mentions for Silverback Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 beat MediciNova's score of -0.15 indicating that Silverback Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MediciNova	Neutral
Silverback Therapeutics	Neutral

MediciNova has higher revenue and earnings than Silverback Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$920.48K	83.95	-$12M	-$0.21	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

MediciNova presently has a consensus price target of $8.33, indicating a potential upside of 430.79%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silverback Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Silverback Therapeutics	N/A	-29.62%	-28.20%

9.9% of MediciNova shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MediciNova has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Summary

MediciNova beats Silverback Therapeutics on 11 of the 16 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$77.28M	$12.57B	$7.33B	$12.76B
Dividend Yield	N/A	2.61%	2.54%	10.78%
P/E Ratio	-7.48	778.10	271.22	24.16
Price / Sales	83.95	958.56	696.48	128.34
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	1.85	10.54	11.33	6.51
Net Income	-$12M	$2.80B	$3.46B	$347.63M
7 Day Performance	17.16%	2.70%	2.92%	1.50%
1 Month Performance	18.94%	5.60%	8.55%	5.15%
1 Year Performance	18.94%	8.62%	27.54%	17.73%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	1.752 of 5 stars	$1.57 +2.6%	$8.33 +430.8%	+16.6%	$77.28M	$920.48K	N/A	10
ZNTL Zentalis Pharmaceuticals	3.5325 of 5 stars	$3.68 -0.5%	$6.75 +83.4%	+88.9%	$255.15M	$67.43M	N/A	160
ACB Aurora Cannabis	1.4323 of 5 stars	$3.67 +1.9%	N/A	-21.0%	$238.62M	$247.82M	N/A	1,028
SLGL Sol-Gel Technologies	3.6475 of 5 stars	$79.33 -4.4%	$197.50 +149.0%	+241.4%	$237.97M	$19.39M	N/A	50	Earnings Report
ANTX Anthem	2.0159 of 5 stars	$5.97 +4.2%	$9.00 +50.8%	+396.0%	$226.04M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. ZNTL, ACB, SLGL, ANTX, and SBTX

How does MediciNova compare to Zentalis Pharmaceuticals?

Summary

How does MediciNova compare to Aurora Cannabis?

Summary

How does MediciNova compare to Sol-Gel Technologies?

Summary

How does MediciNova compare to Anthem?

Summary

How does MediciNova compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. ZNTL, ACB, SLGL, ANTX, and SBTX

How does MediciNova compare to Zentalis Pharmaceuticals?

Does the media favor ZNTL or MNOV?

Do institutionals and insiders hold more shares of ZNTL or MNOV?

Which has more volatility & risk, ZNTL or MNOV?

Do analysts rate ZNTL or MNOV?

Is ZNTL or MNOV more profitable?

Which has higher valuation & earnings, ZNTL or MNOV?

Summary

How does MediciNova compare to Aurora Cannabis?

Does the media refer more to MNOV or ACB?

Which has more risk & volatility, MNOV or ACB?

Do institutionals and insiders hold more shares of MNOV or ACB?

Do analysts recommend MNOV or ACB?

Which has better valuation and earnings, MNOV or ACB?

Is MNOV or ACB more profitable?

Summary

How does MediciNova compare to Sol-Gel Technologies?

Does the media refer more to MNOV or SLGL?

Do analysts recommend MNOV or SLGL?

Is MNOV or SLGL more profitable?

Which has more volatility and risk, MNOV or SLGL?

Which has preferable valuation and earnings, MNOV or SLGL?

Do institutionals & insiders believe in MNOV or SLGL?

Summary

How does MediciNova compare to Anthem?

Which has more volatility & risk, ANTX or MNOV?

Does the media prefer ANTX or MNOV?

Is ANTX or MNOV more profitable?

Do institutionals & insiders hold more shares of ANTX or MNOV?

Which has better earnings and valuation, ANTX or MNOV?

Do analysts rate ANTX or MNOV?

Summary

How does MediciNova compare to Silverback Therapeutics?

Does the media favor MNOV or SBTX?

Which has stronger earnings & valuation, MNOV or SBTX?

Do analysts prefer MNOV or SBTX?

Is MNOV or SBTX more profitable?

Do insiders and institutionals hold more shares of MNOV or SBTX?

Which has more risk & volatility, MNOV or SBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools